Immunicom Hires World-Renowned Oncologist to Rapidly Progress Launch of Non-Pharmaceutical Cancer Therapy

Immunicom’s new Chief Clinical Officer, Victoria Manax M.D., developed and launched drugs in various therapeutic areas, including the standard of care for pancreatic cancer, Abraxane Dr. Manax is well-recognized for oncology master protocol studies with global regulatory agencies, including U.S. FDA SAN DIEGO, August 31, 2021 – Immunicom, Inc., a clinical stage biotech pioneering non-pharmaceutical immunotherapies, hires Dr. … Continued

Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)

Immunopheresis™️ therapy holds great promise for avoiding serious drawbacks of existing pharmaceuticals and improving patients’ quality of life SAN DIEGO, March 23, 2021 – Immunicom, Inc., a global biotechnology company pioneering novel “subtractive” immunotherapies, today announced that the ImmunopheresisTM LW-02 blood-filtering column, its leading immuno-oncology product with FDA Breakthrough Device status, has received regulatory clearance (CE Mark … Continued

Immunicom CEO Amir Jafri Named a Top Healthcare Leader in CEO Today Healthcare Awards

SAN DIEGO – Oct. 20, 2020 – Immunicom, Inc. Founder and CEO, Amir Jafri, has been named one of the top eight healthcare leaders by CEO Today Magazine in its 2020 Healthcare Awards. Jafri was recognized for his vital healthcare contributions in developing novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis™ technology platform. The Immunopheresis approach is a … Continued

Immunicom CEO Featured in Fireside Chat with U.S. Rep. Dan Crenshaw, Following Speech by Nobel Laureate James Allison

SAN DIEGO, Calif., March 11, 2020 /PRNewswire/ — Amir Jafri, CEO of Immunicom, Inc., a medical technology company that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, was one of five exclusively invited guest panelists at Congressman Dan Crenshaw’s second annual Healthcare Innovation Summit held at Rice University. The summit showcased cutting-edge research that highly … Continued

Immunicom Secures $11 Million in Series B Investment Round

SAN DIEGO, July 2, 2019 /PRNewswire/ — Immunicom, Inc., a biotechnology company awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating late-stage metastatic cancer, raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom’s overall capital raised to $20 million. “Proceeds from this financing will help fund … Continued

Immunicom’s Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer

SAN DIEGO, May 14, 2018 /PRNewswire/ — Immunicom, Inc., a medical technology company developing revolutionary non-pharmaceutical approaches for treating cancer and autoimmune diseases, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Immunopheresis™ therapy, which is based on a proprietary technology that selectively removes immune inhibitors from a patient’s bloodstream potentially enabling their natural … Continued